High-sensitivity Niche Target emergency departments and critical care units with Brava's high-sensitivity troponin test that delivers lab-quality results at the point-of-care within 15 minutes, addressing ESC and ACC guideline shifts.

Early-stage Financing Identify potential investors and strategic partners focused on early-stage medical devices to fund complete product development and clinical trials for rapid multiplex POC assays.

Strategic Partnerships Leverage MBio Diagnostics legacy and the LightDeck merger to approach hospital systems and distributors as a combined-brands value proposition for faster adoption and credibility.

Cost-effective Platform Position the evanescent planar waveguide technology as a low-cost instrument with high-margin, disposable cartridges to drive favorable total cost of ownership for EDs and urgent care centers.

Competitive Positioning Differentiate from traditional central-lab and existing POC tests by offering comparable sensitivity and faster turnaround, creating opportunities in competitive bids and procurement cycles for acute care diagnostics.